NeuExcell, Spark to Develop Neuroregenerative Gene Therapy

NeuExcell, Spark to Develop Neuroregenerative Gene Therapy

308849

NeuExcell, Spark to Develop Neuroregenerative Gene Therapy

NeuExcell Therapeutics has entered into a research deal with Spark Therapeutics to advance the development of a safe and effective neuroregenerative gene therapy for Huntington’s disease. Under the terms of the agreement, Spark, a member of the Roche Group, will have access to NeuExcell’s gene therapy platform and hold an option to license the exclusive global rights over its Huntington’s disease program. In exchange, NeuExcell will be eligible to receive an upfront payment, license fees,…

You must be logged in to read/download the full post.